Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: A randomized clinical trial

被引:61
作者
Cheng, Alan [1 ]
Nazarian, Saman [1 ]
Brinker, Jeffrey A. [1 ]
Tompkins, Christine [1 ]
Spragg, David D. [1 ]
Leng, Charles T. [1 ]
Halperin, Henry [1 ]
Tandri, Harikrishna [1 ]
Sinha, Sunil K. [1 ]
Marine, Joseph E. [1 ]
Calkins, Hugh [1 ]
Tomaselli, Gordon F. [1 ]
Berger, Ronald D. [1 ]
Henrikson, Charles A. [1 ]
机构
[1] Johns Hopkins Med Inst, Div Cardiol, Sect Cardiac Electrophysiol, Baltimore, MD 21205 USA
关键词
ICD; Pacemaker; Anticoagulation; Heparin; Warfarin; Bleeding; Stroke; ORALLY ANTICOAGULATED PATIENTS; AMERICAN-HEART-ASSOCIATION; MOLECULAR-WEIGHT HEPARIN; DEVICE IMPLANTATION; PERIOPERATIVE MANAGEMENT; THERAPY; SURGERY; GUIDE; RISK; INTERRUPTION;
D O I
10.1016/j.hrthm.2010.12.016
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
BACKGROUND Management of oral anticoagulation in patients undergoing pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) implantation remains controversial. Prior studies demonstrate that continuation of warfarin may be safer when compared with strategies requiring interruption and/or heparin bridging. Limited data from randomized trials exist. OBJECTIVE We conducted a randomized trial to determine whether warfarin continuation is superior to warfarin interruption during PPM or ICD implantation. METHODS Patients on oral anticoagulation referred for PPM or ICD implantation were randomized to warfarin continuation versus interruption. Patients randomized to warfarin interruption were further stratified into two groups based on their risk for thromboembolic events in the absence of warfarin. Moderate-risk patients were randomized to warfarin continuation versus warfarin interruption. High-risk patients were randomized to warfarin continuation versus warfarin interruption with heparin bridging. The primary combined outcome included thromboembolic events, anticoagulant-related complications, or any significant bleeding necessitating additional intervention or discontinuation of anticoagulation. RESULTS We studied 100 patients (average age 70.8 years, 21% female, mean body mass index 28.4) who underwent 64 ICD and 36 PPM implantations. Fifty patients were assigned to continue warfarin. The randomized groups were well matched. Among patients randomized to warfarin interruption, there were two pocket hematomas, one pericardial effusion, one transient ischemic attack, and one patient who developed heparin-induced thrombocytopenia. No events were noted among patients continuing warfarin (P = .056). CONCLUSIONS While the results were not statistically significant, there was a trend toward reduced complications in patients randomized to warfarin continuation. This strategy should be considered in patients undergoing PPM or ICD implantation.
引用
收藏
页码:536 / 540
页数:5
相关论文
共 22 条
[1]
Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation [J].
Ahmed, Imdad ;
Gertner, Elie ;
Nelson, William B. ;
House, Chad M. ;
Dahiya, Ranjan ;
Anderson, Christopher P. ;
Benditt, David G. ;
Zhu, Dennis W. X. .
HEART RHYTHM, 2010, 7 (06) :745-749
[2]
Implantation of pacemakers and implantable cardioverter defibrillators in orally anticoagulated patients [J].
Al-Khadra, AS .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2003, 26 (01) :511-514
[3]
Prospective randomized comparison of the safety and effectiveness of placement of endocardial pacemaker and defibrillator leads using the extrathoracic subclavian vein guided by contrast venography versus the cephalic approach [J].
Calkins, H ;
Ramza, BM ;
Brinker, J ;
Atiga, W ;
Donahue, K ;
Nsah, E ;
Taylor, E ;
Halperin, H ;
Lawrence, JH ;
Tomaselli, G ;
Berger, RD .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2001, 24 (04) :456-464
[4]
Acute Lead Dislodgements and In-Hospital Mortality in Patients Enrolled in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry [J].
Cheng, Alan ;
Wang, Yongfei ;
Curtis, Jeptha P. ;
Varosy, Paul D. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (20) :1651-1656
[5]
Perioperative Management of Anticoagulation during Device Implantation-The UK Perspective [J].
de Bono, Joseph ;
Nazir, Sheraz ;
Ruparelia, Neil ;
Bashir, Yaver ;
Betts, Tim ;
Rajappan, Kim .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2010, 33 (04) :389-393
[6]
The perioperative management of antithrombotic therapy [J].
Douketis, James. D. ;
Berger, Peter B. ;
Dunn, Andrew S. ;
Jaffer, Amir K. ;
Spyropoulos, Alex C. ;
Becker, Richard C. ;
Ansell, Jack .
CHEST, 2008, 133 (06) :299S-339S
[7]
Risk of thromboembolism with short-term interruption of warfarin therapy [J].
Garcia, David A. ;
Regan, Susan ;
Henault, Lori E. ;
Upadhyay, Ashish ;
Baker, Jaclyn ;
Othman, Mohamed ;
Hylek, Elaine M. .
ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (01) :63-69
[8]
Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy [J].
Giudici, MC ;
Barold, SS ;
Paul, DL ;
Bontu, P .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2004, 27 (03) :358-360
[9]
Outpatient pacemaker procedures in orally anticoagulated patients [J].
Goldstein, DJ ;
Losquadro, W ;
Spotnitz, HM .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1998, 21 (09) :1730-1734
[10]
American Heart Association American College of Cardiology - Foundation guide to warfarin therapy [J].
Hirsh, J ;
Fuster, V ;
Ansell, J ;
Halperin, JL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (09) :1633-1652